A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
Polymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed, combined...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3202563?pdf=render |
| _version_ | 1818611139178659840 |
|---|---|
| author | Graeme J M Cowan Alison M Creasey Kelwalin Dhanasarnsombut Alan W Thomas Edmond J Remarque David R Cavanagh |
| author_facet | Graeme J M Cowan Alison M Creasey Kelwalin Dhanasarnsombut Alan W Thomas Edmond J Remarque David R Cavanagh |
| author_sort | Graeme J M Cowan |
| collection | DOAJ |
| description | Polymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed, combined with the relatively conserved Block 1 sequence of MSP-1 and expressed in E.coli. The MSP-1 Hybrid antigen has been produced with high yield by fed-batch fermentation and purified without the aid of affinity tags resulting in a pure and extremely thermostable antigen preparation. MSP-1 hybrid is immunogenic in experimental animals using adjuvants suitable for human use, eliciting antibodies against epitopes from all three Block 2 serotypes. Human serum antibodies from Africans naturally exposed to malaria reacted to the MSP-1 hybrid as strongly as, or better than the same serum reactivities to individual MSP-1 Block 2 antigens, and these antibody responses showed clear associations with reduced incidence of malaria episodes. The MSP-1 hybrid is designed to induce a protective antibody response to the highly polymorphic Block 2 region of MSP-1, enhancing the repertoire of MSP-1 Block 2 antibody responses found among immune and semi-immune individuals in malaria endemic areas. The target population for such a vaccine is young children and vulnerable adults, to accelerate the acquisition of a full range of malaria protective antibodies against this polymorphic parasite antigen. |
| first_indexed | 2024-12-16T15:25:34Z |
| format | Article |
| id | doaj.art-a98aaea91866421cb44dbb8a305cd9b1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T15:25:34Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a98aaea91866421cb44dbb8a305cd9b12022-12-21T22:26:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2661610.1371/journal.pone.0026616A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.Graeme J M CowanAlison M CreaseyKelwalin DhanasarnsombutAlan W ThomasEdmond J RemarqueDavid R CavanaghPolymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed, combined with the relatively conserved Block 1 sequence of MSP-1 and expressed in E.coli. The MSP-1 Hybrid antigen has been produced with high yield by fed-batch fermentation and purified without the aid of affinity tags resulting in a pure and extremely thermostable antigen preparation. MSP-1 hybrid is immunogenic in experimental animals using adjuvants suitable for human use, eliciting antibodies against epitopes from all three Block 2 serotypes. Human serum antibodies from Africans naturally exposed to malaria reacted to the MSP-1 hybrid as strongly as, or better than the same serum reactivities to individual MSP-1 Block 2 antigens, and these antibody responses showed clear associations with reduced incidence of malaria episodes. The MSP-1 hybrid is designed to induce a protective antibody response to the highly polymorphic Block 2 region of MSP-1, enhancing the repertoire of MSP-1 Block 2 antibody responses found among immune and semi-immune individuals in malaria endemic areas. The target population for such a vaccine is young children and vulnerable adults, to accelerate the acquisition of a full range of malaria protective antibodies against this polymorphic parasite antigen.http://europepmc.org/articles/PMC3202563?pdf=render |
| spellingShingle | Graeme J M Cowan Alison M Creasey Kelwalin Dhanasarnsombut Alan W Thomas Edmond J Remarque David R Cavanagh A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. PLoS ONE |
| title | A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
| title_full | A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
| title_fullStr | A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
| title_full_unstemmed | A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
| title_short | A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
| title_sort | malaria vaccine based on the polymorphic block 2 region of msp 1 that elicits a broad serotype spanning immune response |
| url | http://europepmc.org/articles/PMC3202563?pdf=render |
| work_keys_str_mv | AT graemejmcowan amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alisonmcreasey amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT kelwalindhanasarnsombut amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alanwthomas amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT edmondjremarque amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT davidrcavanagh amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT graemejmcowan malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alisonmcreasey malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT kelwalindhanasarnsombut malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alanwthomas malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT edmondjremarque malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT davidrcavanagh malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse |